Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cultured artificial red blood cells (animal)
- Development stage
- Preclinical
- Lead developer
- RedGene
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Cultured artificial red blood cells (animal) is a preclinical-stage cell therapy being developed by RedGene, a South Korean biotechnology company. The product consists of in vitro-cultured artificial red blood cells (cRBC) derived from animal immortalized adult erythroid progenitors. It is designed as a universal blood supply solution for veterinary blood transfusions, particularly for companion animals such as dogs and cats, to provide a safe, compatible, and donor-independent alternative to traditional blood transfusions.
- Other names
- Animal Cultured RBCCanine Cultured RBCcultured artificial RBC (animal)
Beyond the preview
Go deeper on cultured artificial red blood cells (animal).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cultured artificial red blood cells (animal).